Prognostic Value of the Pretreatment Gustave Roussy Immune (GRIm) Score in Metastatic or Recurrent Gastric Cancer Treated with First-Line Chemotherapy

Cancer that has spread beyond its original site is a formidable challenge for doctors and patients alike. Even with modern medicines, the course of the disease can be unpredictable; two people with seemingly similar tumors may respond very differently to the same treatment. This unpredictability often stems from the complex relationship between a tumor and the body it inhabits. Tumors do not exist in isolation; they interact with the body's immune system, its nutritional state, and its metabolic processes. These interactions leave traces in the blood, creating a biological signature that reflects how aggressive the cancer is and how well the body is holding up against it. Scientists have long sought simple ways to read these signatures, hoping to find a clear signal that predicts who will fare well and who will struggle, allowing for better planning of care before a single dose of medicine is given.

In a recent study published by researchers at Sanko University, a team of oncologists looked closely at a specific blood-based tool called the Gustave Roussy Immune score, or GRIm score, to see if it could offer such clarity for patients with advanced stomach cancer. This score is not a complex genetic test or an expensive scan; it is a simple calculation derived from three routine blood measurements taken before treatment begins. The first measurement is the ratio of two types of white blood cells, neutrophils and lymphocytes, which acts as a gauge for the body's level of inflammation and its ability to fight back. The second is the level of albumin, a protein that reflects a patient's nutritional health and strength. The third is the level of lactate dehydrogenase, an enzyme that rises when cells are breaking down rapidly, often a sign of a heavy tumor burden. By combining these three numbers, doctors can assign a score that places a patient into a low-risk or high-risk category. The researchers wanted to know if this simple score could accurately predict how long patients with metastatic or recurrent stomach cancer would survive and how long their disease would stay under control after starting their first round of chemotherapy.

The team reviewed the medical records of 145 patients treated between 2014 and 2024. All these individuals had stomach cancer that had either spread to other parts of the body at the time of diagnosis or had returned after a period of remission. Every patient received a standard first-line chemotherapy regimen, which typically combines drugs that interfere with cell division. The researchers calculated the GRIm score for each person based on blood tests taken just before they started treatment. They then followed these patients to see how long they lived and how long it took for their cancer to grow again. The results were striking. Patients with a high GRIm score, indicating a combination of high inflammation, poor nutrition, and high metabolic activity, had significantly worse outcomes than those with a low score. The group with the high score saw their disease progress much faster, with a median time to progression of just three months, compared to six months for the low-score group. More importantly, their overall survival was shorter; the high-risk group lived for a median of eight months, while the low-risk group lived for a median of twelve months.

Beyond just survival times, the score also predicted how well the chemotherapy would work. When the researchers looked at whether the treatment successfully stopped the cancer from growing or shrank the tumors, they found that the high-risk group responded much less often. Only half of the patients with a high GRIm score achieved disease control, whereas nearly two-thirds of the low-risk group saw their cancer stabilize or shrink. The study also examined other factors, such as where the cancer had spread and how the cells looked under a microscope. While the presence of cancer in the lining of the abdomen and the spread to multiple organs were also strong predictors of poor survival, the GRIm score remained a powerful independent factor. Even when the researchers accounted for these other serious conditions, a high GRIm score still signaled a higher risk of death. One notable finding was that patients with high scores were much more likely to have cancer that had spread to the bones, a detail that stood out even though bone metastasis itself did not independently predict survival in the final statistical model.

The researchers were careful to note the limits of their work. Because this was a look back at past records from a single hospital, there is a chance that the group of patients studied was not perfectly representative of all people with stomach cancer. They also noted that they did not have data on the patients' general physical fitness, a factor known to be crucial in cancer outcomes, which means the score's power might be slightly mixed with that missing information. Furthermore, none of the patients in this study received modern immunotherapy drugs as their first treatment, so the findings apply specifically to those receiving standard chemotherapy. Despite these limitations, the study suggests that the GRIm score is a valuable, low-cost tool. It offers a way to identify patients who are likely to have a harder time with standard treatment, potentially allowing doctors to prepare for a more difficult course or to consider different strategies sooner. The authors conclude that while this score shows great promise for helping doctors understand the risks facing their patients, it needs to be tested in larger, forward-looking studies before it becomes a standard part of everyday medical practice.